1. 1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC). (September 2015) Authors: Vuylsteke, P.; Huizing, M.; Petrakova, K.; Roylance, R.; Laing, R.; Chan, S.; Abell, F.; Apt, D.; Zhou, J.; Singel, S.; Fehrenbacher, L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer. Issue 4 (April 2022) Authors: Lerner, A.; Keshwani, K.; Okines, A.; Sanderson, B.; Board, R.E.; Flynn, M.; Sharkey, E.; Konstantis, A.; Roylance, R.; Hanna, D.; King, J.; Murphy, R.; Rehman, F.; Guppy, A.E.; Westbury, C.; Takeuchi, E.; Spurrell, E.; Jayaweera, H.K.; Raja, F. Journal: Clinical oncology Issue: Volume 34:Issue 4(2022) Page Start: 261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Adjuvant Chemotherapy for Breast Cancer in Older Women. Issue 8 (August 2016) Authors: Spurrell, E.; Wilson, P.; Gallagher, C.; Slater, S.; Roylance, R. Journal: Clinical oncology Issue: Volume 28:Issue 8(2016) Page Start: 542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Is Universal Patient Access to Fulvestrant in Hormone Receptor-positive Advanced Breast Cancer Justified? A UK Retrospective Multicentre Study. Issue 8 (August 2020) Authors: Lerner, A.; Keshwani, K.; Sanderson, B.; Board, R.E.; Flynn, M.; Sharkey, E.; Okines, A.; Konstantis, A.; Roylance, R.; Hanna, D.; King, J.; Murphy, R.; Rehman, F.; Guppy, A.; Westbury, C.; Takeuchi, E.; Spurrell, E.; Raja, F. Journal: Clinical oncology Issue: Volume 32:Issue 8(2020) Page Start: e167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Neoadjuvant endocrine treatment and clinical outcome in ER positive breast cancer – a single UK cancer centre experience. (October 2020) Authors: Benafif, S.; Rapti, K.; Nattress, C.; Akay, M.; Roylance, R.; Raja, F.; Spurrell, E.; Konstantis, A.; Papadimitraki, E. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. Issue 2 (February 2019) Authors: Masannat, Y.; Husain, E.; Roylance, R.; Heys, S.D.; Carder, P.; Ali, H.; Maurice, Y.; Pinder, S.; Sawyer, E.; Shaaban, A.M. Journal: European journal of surgical oncology Issue: Volume 45:Issue 2(2019) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Recurrence Data on 373 Cases of Lobular Carcinoma in Situ (LCIS) from the GLACIER Study. Issue 6 (June 2015) Authors: Ep Chaabouni, N. Kebaier; Ruggles, N.; Petridis, C.; Pinder, S.; Roylance, R.; Sawyer, E. Journal: Clinical oncology Issue: Volume 27:Issue 6(2015) Page Start: e13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Trastuzumab Emsantine-related Toxicities and Haemorrhagic Complications in Metastatic Breast Cancer: A Case Series. Issue 6 (June 2018) Authors: Cheng, L.; Raja, F.; Roylance, R.; Stein, R. Journal: Clinical oncology Issue: Volume 30:Issue 6(2018) Page Start: e42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗